Epacadostat Plus Pembrolizumab Shows Early Promise in Advanced RCC

Epacadostat plus pembrolizumab yielded “encouraging response outcomes” among patients with 0 or 1 prior lines of therapy for advanced renal cell carcinoma.

Source: CancerNetwork - June 14, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: News Renal Cell Carcinoma Source Type: news